HR+HER2+青年男性乳腺癌1例暨文献回顾OACSTPCD

Given the rarity of male breast cancer(MBC)worldwide,this study presents a real-world case of a young man with locally advanced HR+HER2+breast cancer and axillary lymph node involvement who received neoadjuvant chemother-apy with TCbHP,exploring the application potential of TCbHP neoadjuvant therapy in MBC.A 31-year-old patient underwent six cycles of TCbHP as neoadjuvant therapy followed by a modified radical mastectomy without postoperative recurrence,demonstrating that TCbHP neoadjuvant therapy has a certain effect in MBC,although its outcomes may differ from those ob-served in female breast cancer.This case report contributes real-world evidence for the use of TCbHP in MBC,and highlights the need for targeted research on specific populations to investigate personalized treatment strategies.In addition,increasing public awareness of MBC,implementing early screening programs,and ensuring timely diagnosis and treatment are critical components for improving the prognosis of MBC patients.Acknowledging the limitations of single-case reports,future studies should include larger cohorts to validate these findings.